DermTech to Present on Genomic Innovation in Dermatology at AHIP 2022
June 14 2022 - 4:05PM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a
leader in precision dermatology enabled by a non-invasive skin
genomics platform, today announced that its chief medical officer,
Dr. Loren Clarke, will present study data illustrating how genomic
technology can enhance melanoma detection and improve patient care
at America’s Health Insurance Plans (AHIP) 2022. The meeting is
being held from June 21-23, 2022 in Las Vegas, Nev.
“Across the spectrum of recent healthcare advancements, genomic
innovations have proven to be more accurate, less invasive and less
expensive than current standards of care,” said Loren Clarke, M.D.,
chief medical officer, DermTech. “We are reshaping the dermatology
landscape by bringing precision, non-invasive solutions to patients
that need better options. Our genomics platform has been shown to
improve diagnostic accuracy, lower the rate of unnecessary
surgeries and improve the ability of clinicians to identify and
treat melanoma early.”
The Company’s session is:
Title - Transforming the Future of Dermatology Through
Genomic Innovation
Speakers – Loren Clarke, M.D., DermTech; Brook Brouha,
M.D., Ph.D., West Dermatology
Presentation Date, Time, Location: June 22, 2022 -
12:15pm PT to 1:00pm PT; Wynn Las Vegas, Pomerol Conference
Room
About DermTech
DermTech is a leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by its non-invasive skin genomics platform. DermTech’s mission is
to improve the lives of millions by providing non-invasive
precision dermatology solutions that enable individualized care.
DermTech provides genomic analysis of skin samples collected
non-invasively using its Smart Stickers™. DermTech markets and
develops products that facilitate the early detection of skin
cancers and is developing products that assess inflammatory
diseases and customize drug treatments. For additional information,
please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations and evaluations with respect to: the
performance, patient benefits, cost-effectiveness,
commercialization and adoption of DermTech’s products and the
market opportunity for these products, DermTech’s positioning and
potential revenue growth, financial outlook and future financial
performance, implications and interpretations of any study results,
and DermTech’s ability to expand its product offerings and develop
pipeline products. These forward-looking statements involve
significant risks and uncertainties that could cause the actual
results to differ materially from the expected results. Most of
these factors are outside of the control of DermTech and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: (1) the outcome of any legal
proceedings that may be instituted against DermTech; (2) DermTech’s
ability to obtain additional funding to develop and market its
products; (3) the existence of favorable or unfavorable clinical
guidelines for DermTech’s tests; (4) the reimbursement of
DermTech’s tests by Medicare and private payors; (5) the ability of
patients or healthcare providers to obtain coverage of or
sufficient reimbursement for DermTech’s products; (6) DermTech’s
ability to grow, manage growth and retain its key employees; (7)
changes in applicable laws or regulations; (8) the market adoption
and demand for DermTech’s products and services together with the
possibility that DermTech may be adversely affected by other
economic, business, and/or competitive factors; and (9) other risks
and uncertainties included in the “Risk Factors” section of the
most recent Annual Report on Form 10-K filed by DermTech with the
Securities and Exchange Commission (the “SEC”), and other documents
filed or to be filed by DermTech with the SEC, including
subsequently filed reports. DermTech cautions that the foregoing
list of factors is not exclusive. You should not place undue
reliance upon any forward-looking statements, which speak only as
of the date made. DermTech does not undertake or accept any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in its expectations or any change in events, conditions, or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220614005392/en/
Steve Kunszabo DermTech (858) 291-1647
steve.kunszabo@dermtech.com
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Apr 2024 to May 2024
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From May 2023 to May 2024